This week Parallax welcomed its first non-physician/researcher guest: health advocate Lindsay Davis. Lindsay, ballerina with ambitions to study at Julliard, was experiencing the symptoms of hypertrophic cardiomyopathy (HCM) from her early teens, but she had not been diagnosed until she was 17.

In this episode Ankur asks Lindsay about her treatment path. Lindsay recalls her own journey to taking control of her condition and the important role of information in patient adherence. Lindsay, former Miss Ohio, talks how she used the pageant to create awareness. Lindsay talks about work in state legislation and her plans for 2021.

In 2020, women still only represent 16% of editorial boards.

US Cardiology Review journal, has recently seen a 7-fold increase in female editorial board members in response to journal-based strategic initiatives and the stellar work of USC editorial board leadership, Ankur Kalra (Editor in Chief) and Bill Gogas (Deputy Editor in Chief), who were keen to drive this change. With thanks to Dr Anastasia Mihailidou’s tenure as a new board member and her suggested nominees, ten new female board members have recently joined US Cardiology Review’s editorial board.

One of the first things painted by the young Mike Gibson, today Professor of Medicine at Harvard, researcher and interventional cardiologist, was a cloud. Years later while painting angiograms Dr Gibson came up with the idea of myocardial blush: The blush was that cloud of dye in the heart muscle.

In this episode, Mike opens up about his childhood in Stilwell, Oklahoma. Ankur and Mike discuss how the inductive quality of art can complement the deductive principles of science. Mike recalls earlier stages of his career and warns about the blinding effect of the ego-driven, competitive culture of cardiology. Ankur asks Mike about fatherhood and about his role as an educator. 

What does it mean to be fearless as a medical professional? How can you protect yourself from the emotional toll of the profession? What is Mike’s advice to early career cardiologists?

Sponsored by Edwards.

In this week’s episode Ankur Kalra asks Dr Suzanne J Baron, Director of Interventional Cardiovascular Research at Lahey Hospital & Medical Center: How do we measure the value of a novel technology?

During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.

In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.

In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research.

How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?